🎥Mo Khan, chief executive of hVIVO #HVO talks to Vox about the company’s plans for a new larger state-of-the-art facility, which will have the capacity increase to 50 quarantine beds with the potential to expand to 70. 🔗Watch here: voxmarkets.co.uk/articles/q-a-w… #AIM

🟣🤝⚫️👀 Orion rebranded the system and soon will rewrite it… Be there on September 14th. @okxweb3 #ORN #OKX #Orion #ComingSoon #BTC #ETH #Crypto #Trading #DeFi #TOKEN2049

hVIVO PLC - Interim results #HVO hVIVO voxmarkets.co.uk/rns/announceme… #voxmarkets #investing #shares #RNS via Vox Markets

Amazing results by #HVO. I really don’t know many, if any, AIM companies that have profit making results like this!

#HVO ✅No debt ✅Market Cap £132m (19.5p) ✅Net cash £31.3m (4.6p) ✅Annual dividend ✅Cash profit margin ⬆️to 19.1% ✅FY 2023 revenue guidance ⬆️ to £55m ✅Expanding capacity: 43 beds in 2023 ➡️70 beds in 2024. £4.5m cost 90% funded by clients (such is demand) 🧵👇

✅H1 revenue growth of 52% to £27.3m (Excl other income of £1.4m + interest on cash) ✅Weighted contracted order book at £78m (record high) - giving 2024 revenue certainty. Orderbook ⬆️quicker than cash❤️‍🔥 ✅FY cash profit estimate of £11m for 2023 and £12.5m for 2024.

✅Looking to use cash mountain to make bolt on acquisitions ✅Is a take over target itself: Current enterprise value to cash profit multiple of 9.1 x & PE ratio of 15.5. (By comparison, Ergomed recently acquired for multiple of 21.1 x & PE ratio of 29.6 based on 2023 forecast)

✅Product range (# challenge models) ⬆️to 11, fully funded by clients (Such is demand, product development undertaken at 0⃣ cost) ✅Can licence unique infectious disease data for AI analysis (to establish new drug development targets) ✅49% share in ph.3 ready universal flu 💉

✅Move to new facility in 2024 will ⬆️operational efficiency (as well as capacity). ✅New laboratory offers ability to enhance offering to non-challenge study customers with cutting-edge virology and immunology labs.

Join the chat - Don't miss out. European Green Transition - Monday 29th April 2024 @ 6pm stream.brrmedia.co.uk/broadcast/6629… Poolbeg Pharma plc - Wednesday 1st May 2024 @ 6pm stream.brrmedia.co.uk/broadcast/6629… Sign up and pre-submit questions European Green Transition Poolbeg Pharma hVIVO

Exclusive option to acquire an orphan drug candidate for #Behçets Disease. ☑️Topical Pentoxifylline to treat oral ulcers ☑️FDA Fast Track & Orphan Designation ☑️Positive Phase 2 data ☑️Potential 505(b)(2) regulatory pathway in the U.S. polaris.brighterir.com/public/poolbeg… #POLB

Our CEO is joined by the CEO of Silk Road Therapeutics on @Proactive_UK: 🤝 Silk Road Therapeutics option agreement 🦠 Behçet's Disease 🔬 Development of tPTX 🧲 Commercial Attraction 👁️ Overview of #POLB full year results youtube.com/watch?v=MOTQwb…

This is a company to watch. #polb #PoolbegPharma

Poolbeg Pharma plc - Wednesday 1st May 2024 @ 6pm stream.brrmedia.co.uk/broadcast/6629… 💥 Not one to miss 💥 Sign up and pre-submit questions European Green Transition Poolbeg Pharma hVIVO

🎉 We received the fully granted patent from the US Patent Office for our Immunomodulator II patent application. The claims cover the treatment & prevention of cytokine storm after an immune response has been triggered - in any disease indication. polaris.brighterir.com/public/poolbeg… #POLB

A company to watch 👀 #EGT #cathalfriel

Last week Scrip, Citeline Commercial covered the option #POLB signed for an orphan drug candidate for #Behçets Disease. Read it here: scrip.citeline.com/SC150193/Deal-… #raredisease #orphandisease #pharma

#POLB it’s retraced 1fib and testing the ATH on the weekly. Rsi, Macd and Aroon direction are all positive. Looking good. DYOR

#kane must be sleeping with the manager. How is he still playing @EURO2024 England

Sick Note Britain LBC Nick Ferrari GB News youtube.com/shorts/aBqlb_v…